VectivBio to Report Full Year 2022 Financial Results and Provide Business Update on Wednesday, April 19, 2023
VectivBio Holding AG (Nasdaq: VECT) announced that it will report financial results for the year ending December 31, 2022, and provide a business update on April 19, 2023, at 8:00 a.m. ET. The company focuses on developing treatments for severe rare conditions, with its lead product candidate, apraglutide, targeting rare gastrointestinal diseases. They are also advancing the CoMET platform for treating inherited metabolic diseases. A live webcast of the conference call will be available on their website, with an archived replay accessible for 30 days after the event.
This announcement highlights VectivBio's commitment to addressing pressing medical needs in rare conditions while providing timely updates for investors.
- VectivBio is pioneering treatments for severe rare conditions, enhancing market potential.
- Lead product candidate apraglutide targets critical rare gastrointestinal diseases.
- Advancement of CoMET platform may address previously undruggable inherited metabolic diseases.
- Potential risks include regulatory delays and impacts from global events like the COVID-19 pandemic and the Russian/Ukrainian war.
Management to Host Conference Call Wednesday, April 19, 2023, at 8.00 a.m. ET
BASEL, Switzerland, April 12, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced they will report financial results for the full year ended December 31, 2022 and provide a business update on Wednesday, April 19, 2023 at 8:00 a.m. ET.
A live webcast will be accessible under ‘Events & Presentations’ in the ‘Investors & Media’ section of VectivBio’s website at ir.vectivbio.com. An archived replay of the webcast will be available on VectivBio’s website approximately two hours after the conference call and will be available for thirty days following the call.
About VectivBio AG
VectivBio is a global clinical-stage biotechnology company focused on transforming and improving the lives of patients with severe rare conditions. Lead product candidate apraglutide is a next-generation, long-acting synthetic GLP-2 analog being developed for a range of rare gastrointestinal diseases where GLP-2 can play a central role in addressing disease pathophysiology, including short bowel syndrome with intestinal failure (SBS-IF) and Acute Graft-Versus-Host Disease (aGVHD).
VectivBio is also advancing its modular, small molecule CoMET platform to address a broad range of previously undruggable Inherited Metabolic Diseases (IMDs). CoMET leverages innovative chemistry, based on a proprietary stabilized pantetheine backbone, to restore fundamental cellular metabolism in pediatric populations with IMDs characterized by a deficit of energy metabolism caused by the depletion of functional Coenzyme A (“CoA”). Candidates from the CoMET platform are initially being evaluated in methylmalonic acidemia (MMA), propionic acidemia (PA), and other organic acidemias.
Forward Looking Statements
Forward-looking statements are statements that are not historical facts. Words and phrases such as “anticipated,” “forward,” “will,” “would,” “may,” “remain,” “potential,” “prepare,” “expected,” “believe,” “plan,” “near future,” “belief,” “guidance,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements concerning the clinical development of apraglutide, as well upcoming data readouts from VectivBio’s STARS and STARGAZE trials, and statements regarding VectivBio’s CoMET platform. All of such statements are subject to risks and uncertainties, many of which are difficult to predict and generally beyond VectivBio’s control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. Such risks and uncertainties include, but are not limited to: the impacts of the Russian/Ukrainian war and the ongoing COVID-19 pandemic, including interruptions or other adverse effects on clinical trials and delays in regulatory review; delay in or failure to obtain regulatory approval of VectivBio’s product candidates and successful compliance with FDA and other governmental regulations applicable to product approvals; the risks inherent in drug development and in conducting clinical trials; and those risks and uncertainties identified in the “Risk Factors” section of VectivBio’s Annual Report for the year ending December 31, 2021 on Form 20-F filed with the Securities and Exchange Commission on April 7, 2022. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, VectivBio undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
VectivBio Contact:
Patrick Malloy
VectivBio SVP, Investor Relations
Patrick.malloy@vectivbio.com
FAQ
What is VectivBio's upcoming conference call date?
What financial results will VectivBio announce?
What is apraglutide?
What is the focus of VectivBio's CoMET platform?
Where can I access the conference call webcast?
